Vancouver, Canada — November 5, 2025 — Leads & Copy — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) announced the filing of a patent application in South Korea for compositions containing its proprietary compound, 5-methoxy-2-aminoindane (MEAI), to treat depression.
The filing expands MEAI’s global intellectual property protection as Clearmind advances its clinical development and commercialization plans. The patent application covers compositions containing MEAI for treating depression.
MEAI is a novel, non-hallucinogenic neuroplastogen that modulates serotonin pathways, promotes neuroplasticity and alleviates depressive symptoms without the psychoactive effects of traditional psychedelics. Major depressive disorder affects over 280 million people globally and remains a leading cause of disability with limited treatment options.
Preclinical studies have demonstrated MEAI’s potential to enhance mood regulation and reduce anhedonia, offering a differentiated approach for patients who do not respond to conventional antidepressants.
Clearmind is a clinical-stage biotech company focused on developing neuroplastogen-derived therapeutics for under-treated health problems, including alcohol use disorder. The company’s intellectual property portfolio consists of 19 patent families including 31 granted patents.
Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine.
Investor Relations: invest@clearmindmedicine.com, Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries: Info@Clearmindmedicine.com
Source: Clearmind Medicine Inc.
